挪威斯沃,利奈唑胺注射液价格（斯沃利奈唑胺）

哪里有卖药品斯沃利奈唑胺的药品的？利奈唑胺注射液价格,利奈唑胺片说明书
【请理解！！！诚信交易】全国各地统一快递送货！！收到快递请当场拆开、如有破损、少发、发错，请当快递员前打电话136****5253！！！我们会马上给您处理~但是、这个问题我们家从来没有发生过，因为我们发货之前都是仔细检查再三的确认，没有任何问题才把产品发出去的！！！这样说，是让亲们可以放心购买136****5253~
斯沃功效：由特定微生物敏感株引起的下列感染：耐万古霉素的屎肠球菌引起的感染，包括并发的菌血症。

院内获得性肺炎，致病菌为金黄色葡萄球菌(甲氧西林敏感或耐甲氧西林的菌株)或肺炎链球菌(包括多药耐药的菌株[MDRSP])。

如果已证实或怀疑存在革兰阴性致病菌感染，临床上可能需要联合用药。

复杂性皮肤和皮肤软组织感染，包括未并发骨髓炎的糖尿病足部感染，由金黄色葡萄球菌(甲氧西林敏感或耐甲氧西林的菌株)、化脓链球菌或无乳链球菌引起。

尚无斯沃用于治疗褥疮的研究。

如果已证实或怀疑存在革兰阴性致病菌感染，临床上应考虑进行联合用药。

非复杂性皮肤和皮肤软组织感染，由金黄色葡萄球菌(仅为甲氧西林敏感的菌株)或化脓链球菌引起。

社区获得性肺炎及伴发的菌血症，由肺炎链球菌(包括对多药耐药的菌株[MDRSP]，多药耐药的肺炎链球菌[MDRSP]是指对于如下2种或更多种抗生素耐药的菌株。

抗生素包括：青霉素、二代头孢菌素、大环内酯类药物、四环素和SMZ/TMP)，或由金黄色葡萄球菌(仅为甲氧西林敏感的菌株)所致。

为减少细菌对药物耐药的发生和保持斯沃及其他抗菌药物的疗效，斯沃应仅用于确诊或高度怀疑敏感菌所致感染的治疗或预防。

当获悉培养和药物敏感性结果，应当考虑选择或调整抗菌治疗。

如缺乏这些资料，当地的流行病学和药物敏感性状况可能有利于经验性治疗的选择！！！避光，密封，在15-30°C(59-86°F)条件下保存。

避免冷冻。

斯沃利奈唑胺注射液如何使用？
Complicated skin and skin and soft tissue infections, community acquired pneumonia and concomitant bacteremia, nosocomial pneumonia (referring to specific pathogens, see indications): adult and youth (aged 12 years and above): 12 hours per 600mg, intravenous or oral; children with * (birth to 11 years old): every 8 hours by oral or intravenous injection of 10mg/kg.Recommended treatment: treatment of 10-14 consecutive days.V ancomycin resistant Enterococcus faecium infection and concomitantbacteremia: adult and youth (aged 12 years and above) 12 hours per 600mg, intravenous or oral; children with * (birth to 11 years old): every 8 hours by oral or intravenous injection of 10mg/kg. Recommendedtreatment: treatment of 14-28 consecutive days. Simple skin and skin and soft tissue infections: adult: every 12 hours of oral 400mg; youth (12 years old): every 12 hours of oral 600mg; children 5-11 years: 10mg/kg per 12 hour oral; children
aged <5 *: 10mg/kg per 8 hour oral. Recommendedtreatment: treatment of 10-14 consecutive days. All oral dose may refer tosilver or silver oral suspension. *<7 days: most neonates born within 7 days of delivery (<34 weeks) patients than in full-term infants and other babysystem on the Seward clearance rate is low, and the AUC value. The initial dose of these newborns should be 10mg/kg, administered every 12 h, whena poor clinical outcome, should be considered according to the dose of 10mg/kg, administered every 8 h. All was born more than 7 days newbornshould according to 10mg/kg, every 8 hour dosing (see pharmacokinetics,special groups, children patients). Adult patients with MRSA infection was600mg, every 12 hours for treatment. In the limited clinical experience in 6 cases of children patients, 5 cases (83%), the infection of gram positivepathogens minimum inhibitory concentration is 4ug/mL, the silver after treatment clinical cure, however. Compared to the adult, pediatric patientswas eliminated rate and systemic drug exposure (AUC) range is wider.When the clinical curative effect in children is not the best, especially theminimum inhibitory concentration of the pathogen is 4ug/mL, in theassessment of curative effect should be considered in its relatively lowsystemic exposure dose, infection and severity, as well as potential disease(see pharmacokinetics, special people, children and children). In a controlled clinical study, infection and treatment scheme of the treatment for7-28 days. All courses by the doctor according to the site of infection andseverity of a patient's response to treatment and to formulate. When nofrom intravenous injection into orally administered dose adjustment. On theapplication of swansoft injection initiation of treatment of patients, doctors can according to the clinical situation, be Siwo tablet or oral suspensioncontinue treatment. Intravenous administration of Swan: intravenous injection should be intravenous infusion in 30-120 minutes. Not theintravenous infusion bag series in other intravenous administrationpathway. Do not add other drugs in the solution. If she needs intravenous injection with other drugs combined application, should according to the recommended dose of each drug and route of administration were used.Method intravenous injection and the following drugs administered through the Y interface, can lead to physical properties are not compatible. These drugs include: amphotericin B, chlorpromazine hydrochloride, diazepam,pentamidine isothionate, erythromycin lactobionate fat, phenytoin sodium and trimethoprim sulfamethoxazole. In addition, the chemical properties ofsilver vein injection with ceftriaxone sodium combined can cause twoincompatible. If the same venous pathway for several drugs areadministered in intravenous injection, application method before and after use, the solution must be infused with silver vein injection and other drugcompatibility (see compatible intravenous injection).
【西藏供应斯沃利奈唑胺片136****5253】拉萨|哪里有卖利奈唑胺、那曲地区|出售利奈唑胺注射液、昌都地区|山南地区|日喀则地区|阿里地区|林芝地区|日喀则|利奈唑胺说明书利奈唑胺价格利奈唑胺英文利奈唑胺片利奈唑胺结构。